We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Depression Tablets 10 and 20 mg
Amitriptyline Major depressive disorders and anxiety Film-coated tablets 10, 25, 50 and 75 mg
Aripiprazole Schizophrenia, bipolar disorder Tablets 5, 10, 15, 20 and 30 mg
Baclofen Spasticity Injection 10 mg/5 ml and 10 mg/20 ml
Baclofen Spasticity Tablets 25 mg
Buprenorphine Opioid dependence 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Clonazepam Epilepsy Oral drops, solution 2.5 mg/ml
Clonazepam Epilepsy Tablets 0.5 and 2 mg
Duloxetine * Major depressive disorders, neuropathic pain, anxiety Gastro resistant hard capsules 30, 60, 90 and 120 mg
Eslicarbazepine Epilepsy Tablets 400 and 1200 mg
Eslicarbazepine acetate Epilepsy Film-coated tablets 800 mg
Ethosuximide Epilepsy, absence seizures Soft capsules 250 mg
Ethosuximide Epilepsy, absence seizures Oral solution 250mg / 5ml
Fampridine Multiple sclerosis XR tablets 10 mg
Fingolimod Multiple sclerosis Capsules 0.5 mg
Flupentixol decanoate Schizophrenia Injection 10mg/ 0,5 ml;  20mg/ ml; 40mg/ ml; 200mg / 10 ml
Lacosamide Epilepsy Oral solution 10 mg/ml syrup
Lamotrigine Lamotrigine XR tablets 25/ 50/ 100/ 200 & 300 mg
Levetiracetam Epilepsy Film-coated tablets 250, 500, 750 and 1000 mg
Levetiracetam Epilepsy Granules for oral solution 250, 500, 750, 1000 and 1500 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.